147 related articles for article (PubMed ID: 37284974)
1. Pharmacokinetics, Pharmacodynamics and Safety of Janagliflozin in Chinese Type 2 Diabetes Mellitus Patients with Renal Impairment.
Zhao H; Zhao Z; He K; Mi N; Lou K; Dong X; Zhang W; Sun J; Hu X; Pang S; Cheng H; Wen Q
Clin Pharmacokinet; 2023 Aug; 62(8):1093-1103. PubMed ID: 37284974
[TBL] [Abstract][Full Text] [Related]
2. Prediction of janagliflozin pharmacokinetics in type 2 diabetes mellitus patients with liver cirrhosis or renal impairment using a physiologically based pharmacokinetic model.
Zhao H; Wei Y; He K; Zhao X; Mu H; Wen Q
Eur J Pharm Sci; 2022 Dec; 179():106298. PubMed ID: 36162752
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, pharmacodynamics and tolerability of single and multiple doses of janagliflozin, a sodium-glucose co-transporter-2 inhibitor, in Chinese people with type 2 diabetes mellitus.
Li X; Zhu X; Liu J; Li Q; Zhang H; Li C; Wu M; Gao L; Wen H; Li X; Tang X; Liu L; Ding Y
Diabetes Obes Metab; 2020 Dec; 22(12):2316-2324. PubMed ID: 32744380
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double-blind, placebo-controlled, Phase 3 trial.
Ji L; Jiang X; Hao Q; Cheng Z; Wang K; Pang S; Liu M; Guo Y; Chen X; Su X; Ning T; Liu J; Bian F; Li Y; Zhang Z; Song W; Sun J
Diabetes Obes Metab; 2023 May; 25(5):1229-1240. PubMed ID: 36594724
[TBL] [Abstract][Full Text] [Related]
5. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus.
Sarashina A; Ueki K; Sasaki T; Tanaka Y; Koiwai K; Sakamoto W; Woerle HJ; Salsali A; Broedl UC; Macha S
Clin Ther; 2014 Nov; 36(11):1606-15. PubMed ID: 25199997
[TBL] [Abstract][Full Text] [Related]
6. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment.
Samukawa Y; Haneda M; Seino Y; Sasaki T; Fukatsu A; Kubo Y; Sato Y; Sakai S
Clin Pharmacol Drug Dev; 2018 Nov; 7(8):820-828. PubMed ID: 29693800
[TBL] [Abstract][Full Text] [Related]
8. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus.
Haneda M; Seino Y; Inagaki N; Kaku K; Sasaki T; Fukatsu A; Kakiuchi H; Sato Y; Sakai S; Samukawa Y
Clin Ther; 2016 Jan; 38(1):66-88.e20. PubMed ID: 26718606
[TBL] [Abstract][Full Text] [Related]
9. Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods.
Song L; Yao X; Liu Y; Zhong W; Jiang J; Liu H; Zhou H; Shi C; Zong K; Wang C; Ma C; Liu D; Hu P
Eur J Pharm Sci; 2020 Apr; 147():105281. PubMed ID: 32126254
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study.
Kashiwagi A; Takahashi H; Ishikawa H; Yoshida S; Kazuta K; Utsuno A; Ueyama E
Diabetes Obes Metab; 2015 Feb; 17(2):152-60. PubMed ID: 25347938
[TBL] [Abstract][Full Text] [Related]
11. A Model-Informed Approach to Accelerate the Clinical Development of Janagliflozin, an Innovative SGLT2 Inhibitor.
Song L; Wang X; Sun J; Hu X; Li H; Hu P; Liu D
Clin Pharmacokinet; 2023 Mar; 62(3):505-518. PubMed ID: 36802026
[TBL] [Abstract][Full Text] [Related]
12. Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.
Groop PH; Del Prato S; Taskinen MR; Owens DR; Gong Y; Crowe S; Patel S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2014 Jun; 16(6):560-8. PubMed ID: 24612167
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
He YL
Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.
Macha S; Mattheus M; Halabi A; Pinnetti S; Woerle HJ; Broedl UC
Diabetes Obes Metab; 2014 Mar; 16(3):215-22. PubMed ID: 23859488
[TBL] [Abstract][Full Text] [Related]
15. The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus.
Sahasrabudhe V; Terra SG; Hickman A; Saur D; Shi H; O'Gorman M; Zhou Z; Cutler DL
J Clin Pharmacol; 2017 Nov; 57(11):1432-1443. PubMed ID: 28703316
[TBL] [Abstract][Full Text] [Related]
16. Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center.
Sugiyama S; Jinnouchi H; Yoshida A; Hieshima K; Kurinami N; Jinnouchi K; Tanaka M; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
J Clin Med Res; 2019 Apr; 11(4):267-274. PubMed ID: 30937117
[TBL] [Abstract][Full Text] [Related]
17. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
Kasichayanula S; Liu X; Pe Benito M; Yao M; Pfister M; LaCreta FP; Humphreys WG; Boulton DW
Br J Clin Pharmacol; 2013 Sep; 76(3):432-44. PubMed ID: 23210765
[TBL] [Abstract][Full Text] [Related]
18. LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion.
Zambrowicz B; Lapuerta P; Strumph P; Banks P; Wilson A; Ogbaa I; Sands A; Powell D
Clin Ther; 2015 Jan; 37(1):71-82.e12. PubMed ID: 25529979
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.
Kasichayanula S; Chang M; Hasegawa M; Liu X; Yamahira N; LaCreta FP; Imai Y; Boulton DW
Diabetes Obes Metab; 2011 Apr; 13(4):357-65. PubMed ID: 21226818
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.
Marbury TC; Flint A; Jacobsen JB; Derving Karsbøl J; Lasseter K
Clin Pharmacokinet; 2017 Nov; 56(11):1381-1390. PubMed ID: 28349386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
